Related Experiment Video
Updated: Jun 21, 2026

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
Published on: September 7, 2018
TGF-beta and IL-17 serum levels and specific immunotherapy
Giorgio Ciprandi1, Mara De Amici, Simone Negrini
1Department of Internal Medicine, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa, Italy. gio.cip@libero.it
Sublingual Immunotherapy (SLIT) for allergic rhinitis (AR) significantly increases serum TGF-beta levels. This suggests a key role for TGF-beta in AR treatment outcomes, particularly after two years of therapy.
Area of Science:
- Immunology
- Allergology
Background:
- Allergic rhinitis (AR) involves T cell subsets like Th17 and T regulatory cells.
- Sublingual Immunotherapy (SLIT) is an effective AR treatment inducing immunological changes.
Purpose of the Study:
- To evaluate serum IL-17 and TGF-beta levels in AR patients undergoing two years of SLIT.
- To determine the relationship between these cytokines, symptom severity, and drug use.
Main Methods:
- Serum samples collected at baseline, after the first, and after the second pre-seasonal SLIT course.
- Quantification of Interleukin-17 (IL-17) and Transforming Growth Factor-beta (TGF-beta) levels.
- Correlation analysis with AR symptom severity and medication use.
Main Results:
- IL-17 was detectable only in severe allergic rhinitis cases.
- SLIT significantly increased serum TGF-beta levels after two pre-seasonal courses.
- A significant correlation was observed between TGF-beta levels, symptom severity, and drug use.
Conclusions:
- Two pre-seasonal SLIT courses significantly impact serum TGF-beta levels in AR patients.
- TGF-beta modulation may be a key mechanism in SLIT's therapeutic effect.
- TGF-beta levels correlate with clinical outcomes in allergic rhinitis treated with SLIT.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:43Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy
TGF - β Signaling Pathway